PTN

PTN

USD

Palatin Technologies Inc. Common Stock

$0.094-0.009 (-8.641%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$0.103

最高价

$0.107

最低价

$0.087

成交量

0.34M

公司基本面

市值

2.4M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

1.77M

交易所

ASE

货币

USD

52周价格范围

最低价 $0.035当前价 $0.094最高价 $2.13

相关新闻

PR Newswire

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

Palatin Technologies, Inc. (the "Company" or "Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based...

查看更多
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice
PR Newswire

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor...

查看更多
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
PR Newswire

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

查看更多
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
PR Newswire

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

查看更多
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide